• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

    248.12 +0.40 (+0.16%)
    Streaming Delayed Price Updated: 3:14 PM EDT, Jul 8, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Jazz Pharmaceuticals plc - Ordinary Shares

    News headline image
    Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
    From Chimerix, Inc.; Jazz Pharmaceuticals plc
    Via GlobeNewswire
    News headline image
    Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders
    From Autifony Therapeutics Ltd
    Via Business Wire
    Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
    EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
    FN Media Group Presents USA News Group News Commentary Vancouver, BC – September 22, 2023 – USA News Group – Despite the potential federal funding challenges due to the recent debt ceiling deal,... 
    Via FinancialNewsMedia
    Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
    Via Investor Brand Network
    Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
    EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June
    EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END 
    Via FinancialNewsMedia
    News headline image
    The Global Cannabis Pharmaceuticals Market Size Is Expected To Surpass $125 Billion by 2028
    EQNX::TICKER_START (OTCQX:TCNNF),(OTCQX:CURLF),(NASDAQ:TLRY),(NASDAQ:JAZZ) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Topics Cannabis
    News headline image
    Zymeworks Offers Hope for More than Just Long-Term Investors
    Zymeworks stock is up nearly 5% since reporting earnings and a rally that has put ZYME stock over 25% in the last 12 months and could send the stock higher 
    Via MarketBeat
    News headline image
    Struggling Axsome Stock Could Bounce Back on Drug Trial Success
    Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that. 
    Via MarketBeat
    News headline image
    Three CBD Stocks to Dominate a Budding Industry
    The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity. 
    Via MarketBeat
    Topics Cannabis
    New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
    Via Investor Brand Network
    New Drugs in Pipeline for Hypertension, the Silent Global Pandemic
    NetworkNewsWire Editorial Coverage New York, NY – August 10, 2022 – In medicine, there is a term called “clinical inertia,” or the case of what someone doesn’t know — or what they ignore — could kill... 
    Via FinancialNewsMedia
    Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028
    Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,... 
    Via FinancialNewsMedia
    2022 Could be a Banner Year for Biotech Stocks as per top managers (SPRC, HOTH, NLSP, PSTV, IMMX, GNPX, NRBO)
    Via AB Newswire
    Innovators in Pharma Sectors See Potential, Promise in Providing Improved Treatments
    Via FinancialNewsMedia
    Agentix Corp. (AGTX) Signs Deal With NHRI To License CBD-Based Compound To Treat Type 2 Diabetes; Adds Catalyst To Back Half Of 2021
    Via AB Newswire
    Topics Intellectual Property
    Rapid Development of Cannabinoid Based Medicinal Products Reaching New Levels
    Via FinancialNewsMedia
    Topics Cannabis Economy
    This Could Be The Most Exciting Healthcare Development Of The Year
    Via FinancialNewsMedia
    Topics Artificial Intelligence Cannabis
    PAO Group, Inc. Rallies 21% On Monday; Investor Update This Morning Adds Fuel To Bullish Sentiment
    Via AB Newswire
    Topics Cannabis Intellectual Property
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.